<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02650609</url>
  </required_header>
  <id_info>
    <org_study_id>2015-000927-96</org_study_id>
    <nct_id>NCT02650609</nct_id>
  </id_info>
  <brief_title>Treatment of Chronic Subdural Hematoma by Corticosteroids</brief_title>
  <acronym>SUCRE</acronym>
  <official_title>Treatment of Chronic Subdural Hematoma by Corticosteroids</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rennes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rennes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chronic subdural hematomas are a frequent neurosurgical pathology in the elderly. Gold
      standard is surgical evacuation of these hematomas. Physiopathology of chronic subdural
      hematoma involves numerous inflammatory processes which could be inhibited by steroids.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective is to evaluate the efficacy of corticosteroids treatment in patients
      with Chronic subdural hematomas without clinical or radiological signs of severity.

      Secondary objectives are to assess the effect of methylprednisolone on:

        -  quality of life evolution,

        -  morbidity and mortality,

        -  radiological evolution of the lesions.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 24, 2016</start_date>
  <completion_date type="Anticipated">June 24, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 24, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Delay of occurrence of surgical treatment of the Chronic subdural hematomas</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>1, 3 and 6 months</time_frame>
    <description>Short Form Health Survey 12 scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to surgical treatment</measure>
    <time_frame>during the first 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of surgical treatment of the Chronic subdural hematomas</measure>
    <time_frame>1, 3 and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional scales : daily living</measure>
    <time_frame>1, 3 and 6 months</time_frame>
    <description>Instrumental Activities of Daily Living scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional scales : cognitive</measure>
    <time_frame>1, 3 and 6 months</time_frame>
    <description>Mini-Mental State Examination scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional scales : modified Rankin Scale</measure>
    <time_frame>1, 3 and 6 months</time_frame>
    <description>modified Rankin Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma sodium</measure>
    <time_frame>day 0, 7, 14, and 21 and 1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Potassium</measure>
    <time_frame>day 0, 7, 14, and 21 and 1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting glucose</measure>
    <time_frame>day 0, 7, 14, and 21 and 1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of adverse events potentially related to methylprednisolone</measure>
    <time_frame>during the first 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiological improvement</measure>
    <time_frame>1, 3 and 6 months</time_frame>
    <description>Radiological improvement defined by reduction of maximal thickness of hematoma and reduction of midline shift evaluated</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">202</enrollment>
  <condition>Chronic Subdural Hematomas</condition>
  <arm_group>
    <arm_group_label>Methylprednisolone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Methylprednisolone will be supplied as powder and stored in capsules containing 16 mg with lactose as excipient.
Capsules will be administered orally in the morning, during breakfast with a glass of water.
Dose is adapted according to the weight of the patient (1mg/kg):
&lt;60 kg: 3 pills of 16 mg/day
60-80kg: 4 pills of 16 mg/day
&gt;80kg: 5 pills of 16 mg/day The duration of the treatment is 21 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo capsules will only contain lactose. Capsules will be administered orally in the morning, during breakfast with a glass of water.
Dose is adapted according to the weight of the patient (1mg/kg):
&lt;60 kg: 3 pills of 16 mg/day
60-80kg: 4 pills of 16 mg/day
&gt;80kg: 5 pills of 16 mg/day The duration of the treatment is 21 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylprednisolone</intervention_name>
    <arm_group_label>Methylprednisolone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 years old,

          -  With chronic or subacute, uni or bilateral subdural hematoma,

          -  Confirmed by cerebral scan without contrast enhancement,

          -  Without clinical and radiological signs of severity,

          -  Written informed consent from patients or their next of kin according to the patients
             cognitive status.

        Exclusion Criteria:

          -  Diabetics patients,

          -  Contraindication for methylprednisolone,

          -  Previous surgery for chronic subdural hematoma during the past 6 months,

          -  Pre-existing severe dementia related to other etiology than the Chronic subdural
             hematomas,

          -  Existing neurological pathology that can be associated with dementia,

          -  Patients treated with corticosteroids,

          -  Protected person (adults legally protected (under judicial protection, guardianship or
             supervision), person deprived of their liberty, pregnant woman, lactating woman and
             minor),

          -  Participating in other concomitant research.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xavier XM MORANDI, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Rennes</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pierre-Louis PH HENAUX, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Rennes</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pierre-Jean PL LE RESTE, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Rennes</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pascal YR GAUDRON</last_name>
    <phone>02 99 28 25 55</phone>
    <email>drc@chu-rennes.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anne AG GANIVET, MD</last_name>
    <phone>02 99 28 25 55</phone>
    <email>anne.ganivet@chu-rennes.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU Amiens</name>
      <address>
        <city>Amiens</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick TOUSSAINT</last_name>
    </contact>
    <contact_backup>
      <last_name>Cyrille CAPEL</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>CHU Angers</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>CHU Besançon</name>
      <address>
        <city>Besançon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurent THINES</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Bordeaux Neurochirurgie A</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Rodolphe VIGNES</last_name>
    </contact>
    <contact_backup>
      <last_name>Vincent JECKO</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>CHU Bordeaux Neurochirurgie B</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emmanuel CUNY</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Brest</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Phong DAM HIEU</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Caen</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas GABEREL</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>HC Lyon</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emmanuel JOUANNEAU</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AP-HM - Hôpital La Timone</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre-Hugues ROCHE</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Nancy</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Nantes</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric BORD</last_name>
    </contact>
    <contact_backup>
      <last_name>Luc TERREAUX</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>CHU Poitiers</name>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michel WAGER</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Rouen</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sophie CUREY</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Saint Etienne</name>
      <address>
        <city>Saint Etienne</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Romain MANET</last_name>
    </contact>
    <contact_backup>
      <last_name>François VASSAL</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>CHU Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>François PROUST</last_name>
    </contact>
    <contact_backup>
      <last_name>Hélène CEBULA</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>CHU Tours</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick FRANCOIS</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 4, 2016</study_first_submitted>
  <study_first_submitted_qc>January 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 8, 2016</study_first_posted>
  <last_update_submitted>August 25, 2017</last_update_submitted>
  <last_update_submitted_qc>August 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>chronic subdural hematomas</keyword>
  <keyword>surgical treatment</keyword>
  <keyword>corticosteroids</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hematoma</mesh_term>
    <mesh_term>Hematoma, Subdural</mesh_term>
    <mesh_term>Hematoma, Subdural, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

